NCT06893783View on ClinicalTrials.gov

Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2029

Conditions
Neuroendocrine Carcinomas (NEC)Neuroendocrine Carcinoma of PancreasNeuroendocrine Carcinoma of Prostate
Interventions
DRUG

Tarlatamab

1 mg step dose on cycle 1 day 1 10 mg target dose starting cycle 1 day 8, cycle 1 day 15, and every 2weeks thereafter

Trial Locations (4)

05505

RECRUITING

Asan Medical Center, Seoul

Unknown

NOT_YET_RECRUITING

Samsung Medical Center, Seoul

NOT_YET_RECRUITING

Seoul National University Hospital, Seoul

NOT_YET_RECRUITING

Yonsei Severance Hospital, Seoul

All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

lead

Inkeun Park

OTHER

NCT06893783 - Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients | Biotech Hunter | Biotech Hunter